Treatment
Depemokimab clinical trials
We’re tracking 7 recruiting studies that include Depemokimab, each written for real people, not researchers, below.
Recruiting studies
- NCT07671001RecruitingPhase 3
Study of depemokimab for children (6-11) with asthma
This trial tests if a new medicine, depemokimab, can help children aged 6 to 11 whose asthma is not well controlled with their current inhalers and who have a type of inflammation called eosinophilic asthma. It may reduce asthma attacks and improve symptoms.
Mobile, AlabamaAges 6–11 - NCT07456033RecruitingPhase 3
Depemokimab for adults and teens with type 2 asthma
This study tests a new medicine called depemokimab, given as an injection, to see if it can reduce asthma attacks in people with a specific type of asthma (type 2 high). If you have had asthma for several years and have had recent attacks despite using regular inhalers, this trial might be an option for you.
Little Rock, ArkansasAges 12 years+ - NCT05334368RecruitingPhase 3
Depemokimab for hypereosinophilic syndrome with frequent flares
This trial studies depemokimab, a medicine meant to reduce flares in people with hypereosinophilic syndrome (HES). It also checks how safe the treatment is and how well it works over time.
San Diego, CaliforniaAges 18 years+ - NCT07177339RecruitingPhase 3
Testing depemokimab for COPD with type 2 inflammation
This study tests an early treatment called depemokimab for people with moderate to severe COPD who have a type of inflammation linked to high eosinophils. It aims to reduce flare-ups and improve breathing.
Newport Beach, CaliforniaAges 40–75 - NCT06959095RecruitingPhase 3
Depemokimab for COPD with type 2 inflammation
This trial tests a new medicine, depemokimab, given as an injection to help reduce flare-ups (exacerbations) in adults with moderate to severe COPD who have a certain type of inflammation. The goal is to see if it can keep you healthier for longer with fewer serious breathing attacks.
Loxahatchee Groves, FloridaAges 40–80 - NCT06961214RecruitingPhase 3
Testing a new biologic for COPD with type 2 inflammation
This trial tests a medicine called depemokimab for people with COPD and a specific type of inflammation (type 2). It aims to see if it can reduce flare-ups when added to standard inhaler therapy.
Sheffield, AlabamaAges 40–80 - NCT06979323RecruitingPhase 3
Depemokimab study for asthma with imaging and bronchoscopy
This study tests depemokimab, an injectable biologic, to see how it works in the lungs of people with severe asthma. You would get the drug and have special imaging and a bronchoscopy (a tube with a camera placed into your airways to take tiny tissue samples) so doctors can understand how the medicine reduces inflammation.
Brooksville, FloridaAges 18 years+
What Depemokimab is being studied for
Conditions with recruiting Depemokimab studies.
Common questions
- Are there clinical trials studying Depemokimab?
- Yes. Clin2 currently lists 7 recruiting studies that include Depemokimab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Depemokimab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Depemokimab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Depemokimab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.